en · de · es · fr · pt
peptide-index.peptides9002.com › Topic › Selank Handling, Stability, And Analysis — Questions and Answers

Selank Handling, Stability, And Analysis — Questions and Answers

By Editorial Desk · published 2026-07-06 · last reviewed 2026-08-01 · Topic

Everything below concerns heptapeptide. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.

Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.

Selank Handling, Stability, and Analysis

Once dissolved, the peptide is markedly less stable than the dry powder. Aqueous solutions are subject to backbone hydrolysis and to microbial growth when they are handled without sterile technique. Buffered solutions near neutral pH are common for short-term laboratory work, while acidic conditions are sometimes used to improve solubility. Analytical laboratories generally prepare working solutions fresh rather than storing them, and a residual water film left in a reopened vial can seed degradation even when the container appears dry.

Reversed-phase high-performance liquid chromatography is the standard technique for estimating peptide purity. The result is a peak-area percentage, which describes how much of the detected material elutes as the main peak in one run. Mass spectrometry confirms the molecular mass and can reveal truncated, adducted, or otherwise modified species. Amino acid analysis or tandem mass spectrometry can address sequence fidelity when identity is in doubt. None of these measurements, taken alone, establishes that a sample is fit for any specific purpose.

Storage, Analysis, and Regulatory Status

Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography, with mass spectrometry used to confirm molecular mass and sequence information. Amino acid analysis and peptide mapping may supplement these methods. Certified reference standards are scarce, and many commercial lots are sold as research chemicals without a pharmacopoeial monograph. Regulatory treatment differs by country: Selank is a registered prescription medicine in Russia, while in the European Union and the United States it is not an approved drug and may fall under research-chemical or unapproved-product frameworks.

Selank is a hydrophilic peptide and dissolves readily in water and in aqueous buffers. The lyophilised powder is typically a white to off-white solid. Because short peptides are prone to hydrolysis and oxidation, handling benefits from limiting exposure to heat, moisture and strong light. Working solutions are commonly prepared in sterile water or saline, and repeated freeze-thaw cycles are avoided to reduce aggregation and loss of activity. These practices reflect general laboratory convention rather than published stability specifications.

Selank at a glance

PropertyValueNotes
Typical purity specification95 percent or higher by RP-HPLCArea percentage of the main peak
Identity confirmationElectrospray ionization mass spectrometryObserved mass compared with the theoretical value near 751.9 Da
Recommended dry storage-20 °C, desiccated-80 °C for multi-year archival material
Solution handlingPrepare fresh; avoid long storageSterile filtration reduces microbial load
Common synonymsTKPRPGP; TP-7Sequence code and laboratory designation used interchangeably

Background and Peptide Identity

Tuftsin, the parent structure, is a naturally occurring immunomodulatory tetrapeptide released from the Fc region of immunoglobulin G by spleen enzymes. Selank extends this four-residue sequence with three additional amino acids. The stated rationale is that the added tail slows enzymatic breakdown and may influence receptor interactions. How the full heptapeptide behaves at the molecular level is not firmly established, and proposed mechanisms often involve indirect modulation of neurotransmitter or immune signaling rather than a single defined target.

Selank is a synthetic heptapeptide developed in Russia. Its sequence is Thr-Lys-Pro-Arg-Pro-Gly-Pro, a seven-residue chain built around the natural tetrapeptide tuftsin. Researchers at the Institute of Molecular Genetics of the Russian Academy of Sciences first described the compound in the mid-1990s. The design combined the tuftsin core with an added Pro-Gly-Pro tail, a modification intended to extend the molecule's stability in biological fluids. Published work on the peptide has appeared mainly in Russian-language journals.

Related pages on this site

Mechanism and Evidence Base

Pharmacokinetic data are limited. Like most short peptides, Selank is vulnerable to plasma and tissue peptidases, and its measured half-life in circulation is short, on a minutes scale. The Pro-Gly-Pro tail slows this degradation but does not eliminate it. Intranasal administration is the route described in most reports, with absorption through the nasal mucosa and a hypothesized path into the central nervous system that avoids the blood-brain barrier. Direct measurements of human brain exposure are unavailable, so distribution claims rest on inference from animal work.

Clinical evidence comes mainly from small studies conducted in Russia, several of which were open-label or lacked robust blinding. Reported outcomes include lower anxiety scores, changes in attention measures, and effects on asthenic states following illness. Sample sizes are typically in the tens of participants, and independent replication outside the region is scarce. Reviews published in English generally note the limited methodological quality of the underlying trials. Whether the compound produces clinically meaningful effects under rigorous conditions remains unresolved.

Proposed mechanisms center on modulation of the GABA system, but no single molecular target has been confirmed. Rodent studies report changes in GABA-A receptor expression and in the turnover of serotonin, dopamine, and norepinephrine in several brain regions. Increases in brain-derived neurotrophic factor and its receptor have also been described after repeated administration. These findings come largely from animal models, and the degree to which they describe human neurochemistry remains an open question. The mechanism is best characterized as multi-system and not fully resolved.

Selank Origin and Chemical Identity

Regulatory status differs sharply by region. Selank holds a Russian marketing authorization, where it is supplied mainly as nasal drops, while authorities elsewhere have not approved it for medical use. Material sold internationally is therefore usually labeled as a research chemical rather than a medicine. Peer-reviewed publications come predominantly from Russian laboratories, and sample sizes are generally small. Whether the compound produces comparable effects under independent, well-controlled replication remains an open question that the broader literature has not settled.

Selank is a synthetic heptapeptide developed in Russia as a structural analogue of tuftsin, a naturally occurring immunomodulatory tetrapeptide. Its sequence, Thr-Lys-Pro-Arg-Pro-Gly-Pro, keeps the tuftsin core at the N-terminus and appends a Pro-Gly-Pro tail. Researchers at the Institute of Molecular Genetics in Moscow synthesized the compound during the 1990s while searching for peptides with combined anxiolytic and immunomodulatory activity. The added tail was intended to resist enzymatic cleavage and prolong the molecule's presence in circulation.

Background from the literature

=== Internet shutdown === Several human rights organisations including Human Rights Watch (HRW) condemned the al-Burhan-led TMC for shutting down the internet in June 2019. A spokesperson, Shamseldin Kabbashi, stated that the internet would be shut down for a long time because it represented a threat to national security. The move was described by HRW as a "gross violation of human rights". International media saw this as a sign of dictatorship and condemned the act. Many see it as an attempt to hide what al-Burhan's allied militia, known as the Janjaweed, were doing in Khartoum to delay uploading evidence of the violations that took place on 3 June 2019 and in the days that followed.

== History == In 2003, Lifeline Therapeutics, a privately held Denver-based nutraceutical licensing and marketing company, entered into an agreement with Massachusetts biotechnology company CereMedix for the rights to market CMX-1152, an experimental peptide-based compound, under the brand name "Protandim" (also sometimes referred to at that time as "Rholen," "Rejuven8r" and "ependymin"). CereMedix was a ten percent owner of Lifeline and members of the CereMedix management board served on Lifeline's board of directors. CMX-1152 was claimed to upregulate the production of the endogenous antioxidant enzymes superoxide dismutase, catalase, and glutathione peroxidase, and to offset the aging process. CMX-1152 was due to be marketed as an over the counter anti-aging pill in June 2004 after completing human clinical trials. However, plans to market the CMX-1152 version of Protandim fell through and in April 2004 Lifeline Therapeutics announced that it would instead be marketing a different (non-peptide) dietary supplement under the name "Protandim CF" (to distinguish it from the peptide version initially developed by Cermedix). The new version of Protandim, a combination of five common herbal ingredients including turmeric and green tea was invented following "months of extensive research and development" by Lifeline employees Paul Myhill and William Driscoll (a former oil company executive), who together hold the patent on the product, and it was launched in February 2005. Myhill and Driscoll resigned from the company later that year.

=== Pharmacokinetics === The pharmacokinetics of spironolactone have not been studied well, which is in part because it is an old medication that was developed in the 1950s. Nonetheless, much has been elucidated about the pharmacokinetics of spironolactone over the decades.

Kyiv came under air attack in the early hours of the morning. Vitali Klitschko, Kyiv's Mayor, said that debris from intercepted missiles struck the city zoo in the Solomianskyi District and the Shevchenkivskyi District, as well as several cars, and wounded three people. According to Kyiv's military administrator, Serhiy Popko, the attack was "exceptional", as it involved "the maximum number of attack missiles in the shortest period of time." Ukraine stated all eighteen missiles were shot down, including six Kh-47M2 Kinzhal missiles. The attacks came from the north, south and east while being launched from air, land and sea, according to Ukrainian military commander Valerii Zaluzhny. However, Russian Defence Minister Sergei Shoigu dismissed the Ukrainian claims, saying that they had launched a lesser amount of missiles. The Russian Ministry of Defence claimed to have destroyed a US-built Patriot surface-to-air missile defense system with a Kinzhal missile. A US official later told CNN that a Patriot system was likely damaged but not destroyed during the attack, and that assessments for potential damage were ongoing. According to a US official the Patriot system could be repaired in Ukraine. Due to modular nature of the system it may just require the replacement of a damaged component with a new one. Denis Pushilin, head of the Russian-backed Donetsk People's Republic, said that Russian forces had seized several Ukrainian positions near Avdiivka.

=== Bioactive materials and wound healing === Aramwit authored Silk: Properties, Production and Uses in 2012, delving into the applications of silkworm products in medicine and textiles. In 2021, she co-wrote Sustainable Uses of Byproducts from Silk Processing with Narendra Reddy, focusing on the sustainable use of silk by-products across materials, energy, food, cosmetics, and environmental cleanup, with an emphasis on silk proteins in industries like cancer treatment and pharmaceuticals. Her research on silk sericin highlighted fibroin's applications in textiles and biomaterials, alongside discoveries in cosmetics and pharmaceuticals. While examining the effects of different extraction methods on sericin's properties, including cell behavior and collagen production, she found that urea-extracted sericin most effectively reduced melanin content and cellular tyrosinase activity, suggesting its potential use in treating hyperpigmentation. Additionally, she noted sericin's induction of IL-1β and TNF-α in vitro without other inflammatory effects. Aramwit found that sericin reduced inflammation, sped healing, and boosted collagen in rat wounds, with anti-inflammatory effects comparable to betamethasone and calcitriol in her psoriasis study. She later developed eco-friendly agarose and sericin scaffolds for enhanced drug release and wound healing.

Sources: en.wikipedia.org

Reference notes

== Contraindications == Contraindications of elagolix include pregnancy, known osteoporosis, severe hepatic impairment, and concomitant use with strong organic anion-transporting polypeptide (OATP) 1B1 inhibitors such as ciclosporin and gemfibrozil. Elagolix may increase the risk of miscarriage in early pregnancy. Women should avoid pregnancy while taking elagolix, for instance by using birth control, and should discontinue the medication if they become or wish to become pregnant. Elagolix should not be used in women with osteoporosis because it may increase the risk of further bone loss. Severe hepatic impairment is associated with 7-fold increased exposure to elagolix, which may increase the risk of bone loss. In women with moderate hepatic impairment, which is associated with 3-fold increased exposure to elagolix, the medication at 200 mg twice per day should not be used, while 150 mg once per day should be used for no more than 6 months. OATP1B1 inhibitors are likely to greatly increase exposure to elagolix similarly to moderate to severe hepatic impairment. Combined birth control is not contraindicated with elagolix, but because of the estrogen component, is expected to decrease the effectiveness of elagolix in the treatment of endometriosis, and hence is not recommended. Other forms of birth control, such as non-hormonal birth control, can be used instead. Elagolix is not contraindicated in women who are breastfeeding, but it is unknown whether the medication is excreted in breast milk or if it has adverse effects on milk production or the breastfed child.

==== Weight loss ==== Prior to the MERIT study, numerous meta-analyses of studies on ESG report a total body weight loss of approximately 16% at one year. Excess weight loss was observed to be approximately 60% at one year. Weight loss reported from high volume community practices that have both expertise in ESG and robust longitudinal aftercare programs with dietitians have shown even greater outcomes, with total body weight loss approaching 30% and excess weight loss of 66% at one year.

These CSPs are compatible with NP/RP and SFC and also used for analytical, semi-preparative and preparative separations. Many screening research studies conducted at different labs go to suggest that the four CSPs namely Chiralcel OD, Chiralcel OJ, Chiralpak AD, and Chiralpak As are capable of resolving more than 80% of the chiral separations due to their adaptability and high loading capacity. These four polysaccharide chiral stationary stationary phases are referred to as the "golden four". Polysaccharide CSPs are prepared with high quality silica support on to which the polymeric chiral selector (amylose/cellulose dr.) is physically coated (coated CSP) or chemically immobilized (immobilized CSP). Separations can be done in normal phase, reversed-phase, and polar organic mode. While working with coated polysaccharide CSP solvent selection should be done with caution. One should not use drastic solvents such as dichloromethane, chloroform, toluene, ethyl acetate, THF; 1,4-dioxane; acetone; DMSO, etc. These so called "non-standard" solvents will dissolve the silica and irreversibly destroy the stationary phase. The limited resistance of these coated phases to many solvents lead to the development of immobilized polysaccharide CSP. The table below presents some of the immobilized CSP commercially available and with the alternates wherever accessible.

However, this method is not truly analogous to protein structural alignment techniques because it computationally predicts the structures of the RNA input sequences rather than requiring experimentally determined structures as input. Although computational prediction of the protein folding process has not been particularly successful to date, RNA structures without pseudoknots can often be sensibly predicted using free energy-based scoring methods that account for base pairing and stacking.

=== Migraine prophylaxis === Candesartan may be helpful in migraine prevention as it has better tolerability and fewer side effects compared to other first line medications. It has been recommended by multiple guidelines for migraine prophylaxis in adults with different levels of recommendations, however further studies on larger populations are needed.

Sources: en.wikipedia.org

Frequently asked questions

How should selank powder be stored?

Sealed, desiccated storage at -20 °C or colder is the standard recommendation for research-grade material. Vials should reach room temperature before they are opened, which limits condensation. Repeated temperature cycling is discouraged.

Why does purity testing matter?

A reported purity value reflects the share of the main peak in one chromatographic run and says nothing about identity. Confirming that the expected sequence is present requires a separate measurement such as mass spectrometry. Purity and identity are distinct questions.

What does a mass spectrum show?

A mass spectrum reports the molecular masses present in a sample and shows whether they match the value expected for selank, near 751.9 Da. It also flags common artifacts such as truncation or adduct formation. It does not establish correct stereochemistry or complete sequence order on its own.

How should the powder be stored?

Dry powder is normally held at -20 degrees Celsius or below in a sealed, light-protected container with desiccant. Brief room-temperature handling during weighing is generally tolerated. Storage instructions vary between suppliers, so the accompanying certificate of analysis should be followed.

Network